Strong Year-Over-Year Sales Growth
Sales increased 11% year-over-year on both a reported and organic basis, reaching $476 million.
Operating Income and EPS Growth
Adjusted operating income grew 15% year-over-year, while adjusted earnings per share rose by 19% to $1.55.
Cardio & Vascular Segment Performance
Cardio & Vascular sales increased 24% in the second quarter of 2025, driven by new product ramps and acquisitions.
Adjusted Net Income Increase
Adjusted net income for Q2 2025 was $55 million, up 23% year-over-year.
Free Cash Flow Improvement
Free cash flow increased by 55% to $25 million in the second quarter.
Positive Full-Year Outlook
The company expects full-year sales growth of 8% to 9%, adjusted operating income growth of 12% to 16%, and adjusted EPS growth of 18% to 23%.